Palbociclib N-Aldehyde is an intermediate in synthesizing Palbociclib N-b-D-Glucuronide Sodium Salt (P139910), a derivative of Palbociclib (P139900) which is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
参考文献
Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)